TRCT
ARKG icon

Tower Research Capital (TRC)’s ARK Genomic Revolution ETF ARKG Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98M Sell
118,502
-4,361
-4% -$139K 0.12% 145
2026
Q1 		$3.25M Buy
122,863
+65,881
+116% +$1.93M 0.08% 241
2025
Q4 		$1.65M Sell
56,982
-60,521
-52% -$1.82M 0.04% 388
2025
Q3 		$3.26M Buy
117,503
+60,130
+105% +$1.52M 0.09% 190
2025
Q2 		$1.4M Buy
57,373
+39,474
+221% +$865K 0.04% 420
2025
Q1 		$370K Sell
17,899
-234,631
-93% -$5.89M 0.01% 1021
2024
Q4 		$5.95M Buy
252,530
+251,975
+45,401% +$6.2M 0.12% 134
2024
Q3 		$14.2K Sell
555
-109,947
-99% -$2.8M ﹤0.01% 3472
2024
Q2 		$2.59M Buy
110,502
+110,433
+160,048% +$2.79M 0.04% 350
2024
Q1 		$1.98K Sell
69
-16,527
-100% -$497K ﹤0.01% 5147
2023
Q4 		$545K Sell
16,596
-55,451
-77% -$1.51M 0.01% 1303
2023
Q3 		$2.01M Buy
+72,047
New +$2.36M 0.06% 306
2023
Q2 		– Sell
-33,837
Closed -$1.02M – 6028
2023
Q1 		$1.02M Sell
33,837
-81,675
-71% -$2.53M 0.03% 437
2022
Q4 		$3.26M Buy
115,512
+113,169
+4,830% +$3.59M 0.14% 102
2022
Q3 		$77K Sell
2,343
-126,110
-98% -$4.63M ﹤0.01% 2785
2022
Q2 		$4.04M Sell
128,453
-97,862
-43% -$3.42M 0.09% 184
2022
Q1 		$10.4M Buy
226,315
+120,760
+114% +$5.76M 0.1% 174
2021
Q4 		$6.46M Buy
105,555
+4,536
+4% +$314K 0.11% 153
2021
Q3 		$7.55M Buy
101,019
+72,799
+258% +$6.11M 0.19% 71
2021
Q2 		$2.61M Buy
+28,220
New +$2.4M 0.07% 230
2021
Q1 		– Sell
-77,912
Closed -$7.27M – 5378
2020
Q4 		$7.27M Buy
77,912
+56,331
+261% +$4.49M 0.22% 39
2020
Q3 		$1.38M Sell
21,581
-1,743
-7% -$102K 0.02% 690
2020
Q2 		$1.22M Buy
23,324
+8,307
+55% +$356K 0.05% 408
2020
Q1 		$470K Sell
15,017
-22,312
-60% -$746K 0.03% 447
2019
Q4 		$1.25M Sell
37,329
-65,085
-64% -$2.07M 0.1% 90
2019
Q3 		$3.02M Buy
102,414
+77,269
+307% +$2.51M 0.21% 73
2019
Q2 		$867K Buy
+25,145
New +$806K 0.06% 299

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Tower Research Capital (TRC)'s ARKG Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its ARK Genomic Revolution ETF (ARKG) stake by 3.5% in Q2 2026, selling an estimated $139K and leaving 118,502 shares worth $4.98M. The position accounts for 0.12% of the portfolio, ranked #145.

Tower Research Capital (TRC) first reported a position in ARKG in Q2 2019 and has held it in 27 quarters since. The position peaked at $10.4M in Q1 2022. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Tower Research Capital (TRC) held 118,502 shares of ARK Genomic Revolution ETF worth $4.98M as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,361 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $139K.
  • ARK Genomic Revolution ETF made up 0.12% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #145 holding.
  • Tower Research Capital (TRC) first reported a position in ARK Genomic Revolution ETF in Q2 2019 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s ARK Genomic Revolution ETF position peaked at $10.4M in Q1 2022.
  • 272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.